PDCD1 and familial pancreatic carcinoma: Given the promise of SDT as a therapeutic modality and its ability to trigger the induction of an immune response, the value of combining TiSe2-mediated SDT and PD-1 blockade when treating pancreatic cancer in vitro and in vivo was herein evaluated.